Companies › Noucor Health
1 active drug program in 3 registered trials: 1 Phase 1, 1 Phase 3, 1 Phase 2; Genitourinary, Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rupatadine Platelet activating factor receptor antagonist; Histamine H1 receptor antagonist | PTAFR, HRH1 | Phase 1 | Renal Impairment; Rheumatoid Arthritis; Ulcerative Colitis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06708520 | Rupatadine | Phase 1 | Renal Impairment | Genitourinary | Jul 2025 |
| NCT07064707 | Rupatadine | Phase 2 | Ulcerative Colitis | Immunology | Jul 2026 |
| NCT03770923 | Rupatadine | Phase 3 | Rheumatoid Arthritis | Immunology | Oct 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.